BiotechTubeBiotechTube
Home/Pipeline/Bavdegalutamide (ARV-110)

Bavdegalutamide (ARV-110)

Prostate Cancer

Phase 2Active

Key Facts

Indication
Prostate Cancer
Phase
Phase 2
Status
Active
Company
Arvinas

About Arvinas

Arvinas is a leader in the field of targeted protein degradation, founded on groundbreaking research from Yale University. The company's PROTAC® platform enables the development of therapeutics that harness the body's natural protein disposal system to degrade disease-causing proteins, potentially addressing previously 'undruggable' targets. With multiple clinical-stage assets, strategic partnerships, and a robust discovery engine, Arvinas aims to revolutionize treatment for serious diseases in oncology and neurology.

View full company profile

Therapeutic Areas

OncologyNeurology

Other Prostate Cancer Drugs

DrugCompanyPhase
Erleada (apalutamide)Johnson & JohnsonApproved
Nubeqa (darolutamide)BayerApproved
Xtandi (enzalutamide)Astellas PharmaApproved
Proxalutamide (HS-10370)Hansoh PharmaPhase 3
Darolutamide (Nubeqa)Orion CorporationApproved
Relacorilant + EnzalutamideCorcept TherapeuticsPhase 2
NBTXR3NanobiotixPhase 1/2
Praluzatamab ravtansine (CX-2009)CytomX TherapeuticsPhase 1/2
ARV-766ArvinasPhase 2
Alpha DaRTAlpha Tau MedicalPhase 1/2
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials